{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["143(1)"],"submitter":["Gold MR"],"pubmed_abstract":["<h4>Background</h4>The subcutaneous (S) implantable cardioverter-defibrillator (ICD) is safe and effective for sudden cardiac death prevention. However, patients in previous S-ICD studies had fewer comorbidities, had less left ventricular dysfunction, and received more inappropriate shocks (IAS) than in typical transvenous ICD trials. The UNTOUCHED trial (Understanding Outcomes With the S-ICD in Primary Prevention Patients With Low Ejection Fraction) was designed to evaluate the IAS rate in a more typical, contemporary ICD patient population implanted with the S-ICD using standardized programming and enhanced discrimination algorithms.<h4>Methods</h4>Primary prevention patients with left ventricular ejection fraction ≤35% and no pacing indications were included. Generation 2 or 3 S-ICD dev"],"journal":["Circulation"],"pagination":["7-17"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7752215"],"repository":["biostudies-literature"],"pubmed_title":["Primary Results From the Understanding Outcomes With the S-ICD in Primary Prevention Patients With Low Ejection Fraction (UNTOUCHED) Trial."],"pmcid":["PMC7752215"],"pubmed_authors":["Saba S","Gehi A","Knops RE","Hassankhani A","Doshi R","Barr CS","Dinerman J","Greenstein R","Ciuffo A","Stein KM","UNTOUCHED Investigators*","Viani S","Cassidy C","Wright D","Russo AM","Smelley M","Rowe S","Gold MR","Hohnloser S","Mark G","Pasquie JL","Sagi V","El-Chami MF","Busch M","Fedor M","Molin F","Castellano Perez N","Steffel J","Philliopon F","Phelan T","Brock J","Kim B","Clancy J","Kuk R","Irles D","Trojan M","Kim E","Lee M","Henderson R","Rhodes T","Leclercq C","Bhakta D","Varkey S","Chauvin M","Granrud G","Knight B","Rajendra A","Boersma LVA","Al-Ameri H","Merchant F","Moccetti T","Perez-Gil F","Deharo JC","Lee SC","Chinitz J","Nsah E","Upadhyay G","Karanam S","Crossen K","Wiggins S","Klein C","Tabbal G","Weiner S","Bongiorni MG","Lenz C","Huang D","Theuns D","Roberts P","Koide N","Gosau N","Albirini A","Segerson N","Panday M","Badenco N","Kazemian P","Bindra S","Carter N","Timmers L","Tsai S","Aasbo JD","Calvo N","Kalahasty G","Eckardt L","Zadeh A","Bertaux G","Khairallah F","Lewis N","Tendler D","Marzak H","Lewis R","McDonnell K","Gottlieb C","Morani G","Boveda S","Freedman R","Ptaszynski P","Mckenzie J","Mobarek S","Stoltz T","Blangy H","Marquie C","Hamdan F","Lambiase PD","Scott L","Shakir A","Hanon S","Goethals P","Schutzman J","Brisben AJ","Zitron E","Alimohammad R","De Filippo P","Morin D","Weiss R","Schoenhard J","Devecchi F","Ng G","Arias M","Sarter B","Shaik N","Burke MC","Sturdivant JL"],"additional_accession":[]},"is_claimable":false,"name":"Primary Results From the Understanding Outcomes With the S-ICD in Primary Prevention Patients With Low Ejection Fraction (UNTOUCHED) Trial.","description":"<h4>Background</h4>The subcutaneous (S) implantable cardioverter-defibrillator (ICD) is safe and effective for sudden cardiac death prevention. However, patients in previous S-ICD studies had fewer comorbidities, had less left ventricular dysfunction, and received more inappropriate shocks (IAS) than in typical transvenous ICD trials. The UNTOUCHED trial (Understanding Outcomes With the S-ICD in Primary Prevention Patients With Low Ejection Fraction) was designed to evaluate the IAS rate in a more typical, contemporary ICD patient population implanted with the S-ICD using standardized programming and enhanced discrimination algorithms.<h4>Methods</h4>Primary prevention patients with left ventricular ejection fraction ≤35% and no pacing indications were included. Generation 2 or 3 S-ICD dev","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Jan","modification":"2026-04-28T22:53:26.968Z","creation":"2021-02-20T15:06:54Z"},"accession":"S-EPMC7752215","cross_references":{"pubmed":["33073614"],"doi":["10.1161/CIRCULATIONAHA.120.048728"]}}